# Brain-activated CAR-T therapy wipes out childhood cancer in lab studies

> Scientists at UC San Francisco have engineered immune cells that switch on only inside the brain, and they cleared an aggressive childhood cancer in early laboratory tests.

- Published: 2026-11-09 by Tickety-Boo News
- Section: Health
- Location: California, USA
- Web page: https://ticketyboonews.co.uk/stories/brain-activated-car-t-therapy-wipes-out-childhood-cancer-in-lab/
- Original report: [Scientists wipe out deadly brain tumors in every mouse tested with new cancer therapy](https://www.sciencedaily.com/releases/2026/11/261104084009.htm) (ScienceDaily)

## In brief

- UC San Francisco scientists engineered immune cells that activate only inside the brain to attack diffuse midline glioma.
- In early laboratory studies, the therapy completely cleared the childhood cancer and still worked more than 70 days later.
- It has not yet been tested in people; a first clinical trial could begin as early as April 2027.

Researchers at the University of California, San Francisco have created an immune cell therapy that stays dormant until it reaches the brain, and in early laboratory studies it completely cleared an aggressive childhood cancer. The work, published in Science Translational Medicine, centres on diffuse midline glioma (DMG).

DMG grows into the brainstem, which controls breathing, heartbeat and swallowing. Nearly all children diagnosed with it die within a year, and existing treatments have made little headway.

The new therapy is called B-SYNC CAR-T. Ordinary CAR-T treatment modifies a patient's T cells so they can recognise and attack cancer, but it has struggled against brain tumours. The UCSF team built in a molecular switch that responds to brevican, a protein found throughout the brain. Only when the cells meet it do they produce the receptors that hunt down cancer cells carrying the proteins EphA2 or IL13Rα2.

That design appears to keep the treatment quiet elsewhere in the body. "Just as we designed it," said Senthilnath Lakshmanachetty, who led the experiments.

In two laboratory models of DMG, the therapy eliminated the tumours every time it was tested, while conventional CAR-T cells failed to bring them under control. When fresh cancer cells were introduced nearly seven weeks later, they were rejected. The engineered cells were still working more than 70 days on.

The team suspects the delayed switch-on may spare the cells from "exhaustion", the gradual loss of fighting strength that comes with long-term activation. The precise reason for the better performance is not yet clear.

This remains early preclinical research, and it has not yet been tested in people. Still, the researchers are preparing a first clinical trial at UCSF Health that could begin as early as April 2027. It will be led by physicians Marie Jaeger-Krause and Sabine Mueller, and will use each patient's own T cells. Some patients may receive the cells directly into the brain's fluid-filled ventricles through a shunt linked to a reservoir under the scalp, allowing repeat doses without fresh surgery.

## Why it matters

Few families facing DMG have had any real treatment options, so a therapy that targets the cancer precisely and keeps working over time is a welcome step forward. Cells that activate only where they are needed could also lessen the side effects that have held back similar approaches. Laboratory success is no guarantee of results in patients, but moving towards human trials is a cracking start.